JP2023524064A - ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 - Google Patents

ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 Download PDF

Info

Publication number
JP2023524064A
JP2023524064A JP2022566323A JP2022566323A JP2023524064A JP 2023524064 A JP2023524064 A JP 2023524064A JP 2022566323 A JP2022566323 A JP 2022566323A JP 2022566323 A JP2022566323 A JP 2022566323A JP 2023524064 A JP2023524064 A JP 2023524064A
Authority
JP
Japan
Prior art keywords
clofazimine
pharmaceutically acceptable
inhalable
polymorph
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524064A5 (enExample
Inventor
ホフマン トーマス
ウーファ ステファン
ジェイ ジュニア フリーマン ジョン
Original Assignee
マンカインド コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マンカインド コーポレイション filed Critical マンカインド コーポレイション
Publication of JP2023524064A publication Critical patent/JP2023524064A/ja
Publication of JP2023524064A5 publication Critical patent/JP2023524064A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022566323A 2020-05-01 2021-04-30 ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 Pending JP2023524064A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018677P 2020-05-01 2020-05-01
US63/018,677 2020-05-01
PCT/US2021/030155 WO2021222740A1 (en) 2020-05-01 2021-04-30 Clofazimine composition and method for the treatment or prophylaxis of viral infections

Publications (2)

Publication Number Publication Date
JP2023524064A true JP2023524064A (ja) 2023-06-08
JP2023524064A5 JP2023524064A5 (enExample) 2024-05-09

Family

ID=78332269

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566323A Pending JP2023524064A (ja) 2020-05-01 2021-04-30 ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法

Country Status (9)

Country Link
US (1) US20230248722A1 (enExample)
EP (1) EP4142691A4 (enExample)
JP (1) JP2023524064A (enExample)
KR (1) KR20230005937A (enExample)
CN (1) CN115666510A (enExample)
AU (1) AU2021263580A1 (enExample)
BR (1) BR112022022081A2 (enExample)
CA (1) CA3177438A1 (enExample)
WO (1) WO2021222740A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240390366A1 (en) * 2021-11-30 2024-11-28 Mannkind Corporation Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
WO2025091042A1 (en) * 2023-10-27 2025-05-01 Mannkind Corporation Methods for treating non-tuberculous mycobacterial infection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016515522A (ja) * 2013-03-15 2016-05-30 マンカインド コーポレイション 微結晶性ジケトピペラジン組成物および方法
JP2017531673A (ja) * 2014-10-24 2017-10-26 レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． １本鎖ｒｎａウイルス複製を阻害するための治療
CN108853106A (zh) * 2017-05-09 2018-11-23 中国食品药品检定研究院 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途
WO2019070693A1 (en) * 2017-10-02 2019-04-11 Board Of Regents, The University Of Texas System COMPOSITION FOR INHALING CLOFAZIMINE AND METHODS OF USE
WO2019110099A1 (en) * 2017-12-06 2019-06-13 Qrumpharma Inc. Inhalable clofazimine formulation
WO2020040818A1 (en) * 2018-08-23 2020-02-27 Qrumpharma Inc. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071127B2 (en) * 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
EP2496253B1 (en) * 2009-11-02 2019-01-09 MannKind Corporation Apparatus and method for cryogranulating a pharmaceutical composition
CA2943049A1 (en) * 2014-04-08 2015-10-15 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
US20160220710A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016515522A (ja) * 2013-03-15 2016-05-30 マンカインド コーポレイション 微結晶性ジケトピペラジン組成物および方法
JP2017531673A (ja) * 2014-10-24 2017-10-26 レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． １本鎖ｒｎａウイルス複製を阻害するための治療
CN108853106A (zh) * 2017-05-09 2018-11-23 中国食品药品检定研究院 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途
WO2019070693A1 (en) * 2017-10-02 2019-04-11 Board Of Regents, The University Of Texas System COMPOSITION FOR INHALING CLOFAZIMINE AND METHODS OF USE
WO2019110099A1 (en) * 2017-12-06 2019-06-13 Qrumpharma Inc. Inhalable clofazimine formulation
WO2020040818A1 (en) * 2018-08-23 2020-02-27 Qrumpharma Inc. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BANASCHEWSKI BRANDON: "Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacteria", JOURNAL OF CYSTIC FIBROSIS, vol. 18, no. 5, JPN6025027368, May 2019 (2019-05-01), ISSN: 0005781231 *

Also Published As

Publication number Publication date
EP4142691A4 (en) 2024-05-15
US20230248722A1 (en) 2023-08-10
AU2021263580A1 (en) 2022-11-24
EP4142691A1 (en) 2023-03-08
CN115666510A (zh) 2023-01-31
CA3177438A1 (en) 2021-11-04
KR20230005937A (ko) 2023-01-10
WO2021222740A1 (en) 2021-11-04
BR112022022081A2 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
CN102448438A (zh) 抗流行性感冒调配物及方法
FI2265257T4 (fi) Aklidiniumia käsittävä inhalaatiokoostumus kroonisen keuhkoahtaumataudin hoitamiseksi
EP4138832A1 (en) Products of manufacture and methods for treating, ameliorating or preventing microbial infections
UA119774C2 (uk) Комбінації формотеролу і будесоніду для лікування хронічної обструктивної хвороби легень (хохл)
JP2005508963A (ja) 喘息を治療するためのサルメテロールとフルチカゾンプロピオネートを含む医薬の組み合せ
US20250228779A1 (en) Method and composition for treating pulmonary fibrosis
JP2023524064A (ja) ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法
WO2015027848A1 (zh) 含有帕拉米韦和/或其衍生物制剂的给药方法
JP2023544685A (ja) 吸入ルートを介するソフトミスト吸入器又は振動型メッシュ式噴霧器を用いた新型コロナウイルス感染症を含むウイルス性肺疾患の治療における抗ウイルス性、抗マラリア性及び／又は粘液溶解性を備える活性物質の使用
WO2012051050A1 (en) Method for treating cystic fibrosis with inhaled denufosol
Thai et al. Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims
Balducci et al. Drug delivery strategies for pulmonary administration of antibiotics
TW201016215A (en) Compositions and uses of antiviral active pharmaceutical agents
HK40083799A (en) Clofazimine composition and method for the treatment or prophylaxis of viral infections
Das et al. Understanding the Respiratory Delivery of High Dose Anti‐Tubercular Drugs
JP6908523B2 (ja) ネブライザー用組成物
WO2015027847A2 (zh) 含有奥司他韦羧酸胍基类似体和/或其乙酯制剂的给药方法
HK40091740A (zh) 用於治疗、改善或预防微生物感染的制造产品和方法
CN114129546A (zh) 一种吸入用药物组合物
JP2024170686A (ja) 新規医薬
Abdalaziz et al. Formulation strategy for hydroxychloroquine as inhaler dosage from as a potential for COVID-19 treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240424

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420